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Abstract
Background: The extracellular domain of the influenza A virus protein matrix protein 2 (M2e) is remarkably conserved
between various human isolates and thus is a viable target antigen for a universal influenza vaccine. With the goal of
inducing protection in multiple mouse haplotypes, M2e-based multiple antigenic peptides (M2e-MAP) were synthesized to
contain promiscuous T helper determinants from the Plasmodium falciparum circumsporozoite protein, the hepatitis B virus
antigen and the influenza virus hemagglutinin. Here, we investigated the nature of the M2e-MAP-induced B cell response in
terms of the distribution of antibody (Ab) secreting cells (ASCs) and Ab isotypes, and tested the protective efficacy in various
mouse strains.
Methodology/Principal Findings: Immunization of BALB/c mice with M2e-MAPs together with potent adjuvants, CpG 1826
oligonucleotides (ODN) and cholera toxin (CT) elicited high M2e-specific serum Ab titers that protected mice against viral
challenge. Subcutaneous (s.c.) and intranasal (i.n.) delivery of M2e-MAPs resulted in the induction of IgG in serum and airway
secretions, however only i.n. immunization induced anti-M2e IgA ASCs locally in the lungs, correlating with M2-specific IgA
in the bronchio-alveolar lavage (BAL). Interestingly, both routes of vaccination resulted in equal protection against viral
challenge. Moreover, M2e-MAPs induced cross-reactive and protective responses to diverse M2e peptides and variant
influenza viruses. However, in contrast to BALB/c mice, immunization of other inbred and outbred mouse strains did not
induce protective Abs. This correlated with a defect in T cell but not B cell responsiveness to the M2e-MAPs.
Conclusion/Significance: Anti-M2e Abs induced by M2e-MAPs are highly cross-reactive and can mediate protection to
variant viruses. Although synthetic MAPs are promising designs for vaccines, future constructs will need to be optimized for
use in the genetically heterogeneous human population.
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Introduction
B cell responses and the generation of protective Ab titers are
key determinants for antiviral immunity and the basis for
successful vaccination. Current influenza virus vaccines elicit
strong Ab responses against the viral glycoproteins hemagglutinin
(HA) and neuraminidase (NA) and mediate sterile protection
against reinfections with similar viral strains. However, their
efficacy is limited due to the frequent mutations in HA and NA
and the ability of viral subtypes to reassort and thus escape
immune protection. This is highlighted by the recent outbreaks of
avian influenza, emerging new pandemic H1N1 influenza A
viruses, as well as the need to continuously update influenza
vaccines to match the circulating strains. There remains, therefore,
an urgent need to develop vaccines that elicit cross-reactive and
protective immunity by targeting conserved viral proteins.
A promising target for the generation of cross-reactive immunity
to multiple different influenza A viruses is the highly conserved 24-
amino-acid N-terminal extracellular domain of the influenza virus
M2 protein, termed M2 ectodomain (M2e) [1,2]. M2 forms a
disulfide-linked homotetramer in its native form and is expressed
abundantly on the surface of infected cells [3,4,5,6]. Passive transfer
of anti-M2e monoclonal Abs in mice results in restricted viral
replication and protection from viral challenge [5,7,8,9,10,11].
Even under immune pressure in severe combined immunodeficien-
cy (SCID) mice treated with anti-M2e monoclonal Abs, only two
viruses with mutant M2e sequences emerged [9], thus highlighting
the conserved nature of the M2e domain.
Humans have low to undetectable titers of anti-M2e Abs in their
serum indicating that natural infection and current vaccines do not
induce significant levels of anti-M2e Abs [12,13]. To increase
M2e-specific humoral immunity, several vaccination strategies
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peptides, in particular synthetic multiple antigenic peptides (MAPs)
containing M2e-peptides in combination with defined T helper
determinants have been shown to successfully induce anti-M2e
immunity [14,15,16,17,18,19,20,21,22,23,24]. Administration of
M2e-MAPs in conjunction with potent adjuvants such as CpG
ODN and CT, or its derivate CTA1-DD, elicited significant M2e-
specific Ab responses and protected mice from viral challenge.
Other vaccination strategies targeting M2e have been reported
including M2-encoding plasmid DNA [25], M2-expressing recom-
binant viruses or virus-like particles [26,27,28,29,30] and several
fusion proteins that link M2e peptides to immunogenic proteins
[16,31,32,33,34,35] or TLR ligands [36]. Most work with M2e-
vaccine candidates has been performed in BALB/c mice, but a few
studies examined responses in other inbred and outbred mice,
ferrets, pigs or monkeys with varying results in terms of induction of
anti-M2e Ab titers and protection [24,27,30,37,38,39]. Recent
results from Phase I clinical trials have raised hopes for applicability
in humans (for review see [40,41]).
Here we report the construction of a modified design of a M2e-
based MAP vaccine. We investigated the correlates of the
productive B cell response including the distribution of M2e-specific
ASCs after different routes of administration, the Ab isotypes and
their specificity as well as the protective efficacy to challenge with
diverse influenza A viruses in multiple mouse strains.
Results
Improved design and synthesis of M2e-based multi
antigenic peptide (MAPs) with promiscuous T helper
epitopes
The first-generation M2e-based multiple antigenic peptide,
termed M2e-MAP G40d, contained four M2e side chains with the
peptide sequence from influenza virus A/PR/8 (PR8) and two
major PR8 HA T helper epitopes identified in BALB/c mice
assembled on a polylysine-glycine scaffold peptide [14,15]. It was
shown to be highly immunogenic in BALB/c mice. With the aim
to simplify the peptide synthesis and to create a construct that
might be recognized by multiple haplotypes, new M2e-MAPs were
generated. The new constructs were synthesized using an
optimized orthogonal synthesis strategy compatible with conven-
tional solid-phase synthesis that allowed for the generation of a
single piece, multivalent and branched construct [42]. This not
only facilitated the peptide synthesis in comparison to the original
two-piece design that contained an oxidized cysteine-bridge but
also made the final products chemically better defined [14,15].
Two constructs were generated, termed K2 and K3, containing 4
M2e side chains corresponding to the 15 amino acid N-terminus of
M2e from influenza virus PR8 and T helper epitopes identified as
immunogenic peptide sequences from the circumsporozoite
protein in Plasmodium falciparum (CS381–396 and CS327–345), the
hepatitis B virus antigen (HBsAg19–36) and the hemagglutinin of
influenza A virus (HA307–319) (see Table 1). These T helper cell
epitopes are thought to be promiscuous as they can bind multiple
MHC class II haplotypes in mice and humans [43,44,45], and
therefore may induce M2e-specific immunity in a genetically
diverse population. Table 1 and Figure 1A illustrate the new
M2e-MAP composition for K2 and K3 and lists the sequences of
the peptides attached to the side-chains of the scaffold.
Induction of high M2e-specific Ab titers following
immunization with M2e-MAPs in BALB/c mice
To test the ability of K2 and K3 to elicit anti-M2e Ab responses,
BALB/c mice were vaccinated in a prime-boost regimen with 5 mg
of M2e-MAPs in combination with adjuvants CpG 1826 and CT.
Administration of M2e-MAP G40d in combination with these
adjuvants induced protective serum anti-M2e Ab titers in BALB/c
mice [14,15]. We tested the specificity of the elicited Ab response
by two means: first, binding to linear M2e-peptide, cys-M2e, and
secondly binding to cell-surface-expressed native tetrameric M2
protein using a stably transfected cell line, HeLa-M2 [12]. As
measured by both assays, K2 and K3 induced anti-M2e Abs after
two intranasal (i.n.) immunizations that were amplified with an
additional boost (Figure 1B). K2 and K3 induced greater anti-
M2e serum Ab titers as compared to the original M2e-MAP G40d
as previously shown [14,15].
To address whether vaccination with K2 and K3 induced
protection, mice were challenged with influenza virus A/HKx31
(X31) and assayed for infectious virus in their lungs four and five
days later. On day 4 after challenge, K2-immunized mice had
significantly reduced viral titers as compared to a cohort of mice
that received adjuvants alone (Figure 1C). By day 5 after
challenge, the majority of mice that received K2 or K3 in
combination with adjuvants had undetectable level of virus in
their lungs, whereas all mice in the control group exhibited high
viral titers. Similar protection efficacy was also observed for the
first-generation M2e-MAP G40d [14,15]. Nevertheless, as we
show here K2 and K3-immunized mice were protected even
when challenged with the more pathogenic strain PR8
(Figure 1D).
Characterization of the anti-M2e response to different
routes of immunization with M2e-MAPs
Previous reports suggest that the nature of the protective anti-
viral B cell response generated locally in the lungs differs
depending on the route of immunization [14,46]. To determine
the impact of the route of vaccination on the level of Abs in the
lungs versus Ab levels in the serum the M2e-specific Ab responses
to K2 after i.n. and s.c. immunization were compared. Similar
levels of IgG Abs against M2e were detected in the BAL fluid
independent of the route of administration (Figure 2A and data
not shown). S.c. vaccination induced significantly higher levels of
Table 1. M2e-based multiple antigenic peptides (M2e-MAPs).
M2e epitope Tha determinant Thb determinant
Sequence Name Sequence Name Sequence
K2 SLLTEVETPIRNEWG CS381–396 KKIAKMEKASSVFNVV HBsAg19–33 FFLLTRILTIPQSLD
K3 SLLTEVETPIRNEWG CS327–345 YLNKIQNSLSTEWSPCSVT HA307–319 PKYVKQNTLKLAT
M2e-multiple antigenic peptides used in this study were termed K2 and K3. Constructs were synthesized to contain each four copies of the M2e epitope from influenza
virus A/PR/8/34 and two T helper determinants, Tha and Thb (see Figure 1A). Names and corresponding amino acid sequences are listed.
doi:10.1371/journal.pone.0028445.t001
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peptide and HeLa-M2 cells (Figure 2B). M2e-specific IgA Abs
were only detectable in the BAL fluid after i.n. but not s.c.
immunization. M2e-specific IgA was undetectable in sera of
vaccinated mice (data not shown and [14]).
To determine the origin of IgA in BAL after i.n. vaccination, we
developed an enzyme-linked immunosorbent spot (ELISPOT)
assay on plates coated with M2e-peptide to detect M2e-specific
ASCs. ELISPOTs revealed higher numbers of IgA and IgG ASCs
in the lungs after i.n. versus s.c. immunization (Figure 2C). IgG
ASCs were predominantly induced with s.c. immunization and
found in the BM, whereas IgA ASCs in the BM were higher after
i.n. immunization. Similar results were observed with ELISPOTs
on HeLa-M2 cells (data not shown).
Toaddresswhetherthedifferencesintheanti-M2eBcellresponse
elicited by these distinct routes of immunizations had an impact on
protection, mice were challenged with X31 virus and virus titers in
the lungs determined 5 days later. BALB/c mice immunized i.n. or
s.c. with K2 and adjuvants had 100-fold lower viral titers as
compared to mice that received adjuvants alone, however there was
no significant difference between the groups of i.n. or s.c.immunized
mice (Figure 2D). Thus, while i.n. and s.c. immunization with K2
induced different Ab isotypes and ASC localization, mice were
equally well protected against viral challenge.
Figure 1. M2e-based multiple antigenic peptides induce high M2e-Ab titers and elicit protection against viral challenge. (A) Design
of M2e-multiple antigenic peptides K2 and K3 depicting a branched construct of the peptide back-bone (lysine-glycine chain) with each four M2e
residues and two T helper determinants (for sequences see Table 1). (B–D) BALB/c mice (n=4–6/group) were immunized intranasally with M2e-MAP
K2 or K3 mixed with adjuvants (Adj.) or adjuvants alone three times in 3–4 week intervals. (B) Sera were collected 3–4 weeks after the indicated
number of immunization and measured in an ELISA against M2e-peptide or HeLa cells expressing full-length M2 (HeLa-M2). (C and D) 3–4 weeks
after the third vaccination, mice were challenged with (B)5mL of 1000 TCID50 influenza virus A/X31 (2.5 mL/nare) or (D)5 0mL of 1000 TCID50
influenza virus A/PR8. Mice were euthanized 4 or 5 days after challenge as indicated and lungs assayed for infectious virus in MDCK cells.
doi:10.1371/journal.pone.0028445.g001
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sequences
We tested whether immunization with K2 induced Abs able to
recognize cells infected with viruses containing divergent M2e
sequences. Sera from mice immunized i.n. or s.c. with K2 and
adjuvants were assayed for binding to MDCK cells infected in vitro
with the influenza A viruses PR8 and A/FM1/49 (FM) and an
influenza B virus, B/Lee/40. As shown in Figure 3A, M2e from
FM differs by 4 amino acids from PR8-M2e, while M2e from B/
Lee is greater than 95% different from PR8. Equal binding was
observed from serum Abs of mice immunized with K2 and
adjuvants to cells infected with A/PR8 or A/FM and no binding
was measured to B/Lee-infected cells (Figure 3B). There was no
detectable difference between sera from i.n. or s.c. immunized
mice (data not shown).
We extended our studies to test whether K2 induced serum
Abs were able to cross-react with the M2e domain of the
pandemic influenza strain A/Texas/2009 (pH1N1), which has 5-
amino acid differences from the vaccine-encoded PR8-M2e
sequence. Sera from mice immunized s.c. with K2 and adjuvants
displayed significantly more binding than sera from i.n.
immunized mice (Figure 3D), possibly due to higher anti-M2e
IgG serum Ab levels as compared to i.n. immunized mice
(Figure 2B). Our data suggest that immunization with K2
induces different degrees of cross-reactive Abs and that the degree
of binding to specific M2e-target sequences depends on the route
of vaccine administration.
Protection against mutant M2e-escape viruses
Treatment of PR8-infected SCID mice with monoclonal anti-
M2e Abs resulted in the emergence of 2 viruses with mutations at
amino acid position 10 [9]. The M2e-escape mutant virus
designated P10H, has an amino acid change from proline to
histidine at position 10, and the virus termed P10L (Figure 4A)
has a proline to leucine exchange at position 10. To test whether
Abs induced by i.n. administration of K2 recognized these
mutations, sera from K2-immunized mice were tested in an
ELISA against peptides corresponding to parental PR8 (P10) and
mutant viruses. Serum Abs bound to all peptides, although
binding to P10L and P10H was reduced with increasing serum
dilution (Figure 4B). Likewise, serum Abs showed robust binding
to MDCK cells infected in vitro with influenza virus A/PR/8, and
to lesser degrees to cells infected with the mutant viruses P10H and
P10L (Figure 4C). Similar results were obtained with sera from
mice that were s.c. immunized (data not shown). The monoclonal
anti-M2e Ab, 14C2, served as a positive control for binding to
PR8 and FM, whereas it was unable to recognize MDCK cells
infected with the escape mutants as shown previously [9].
To test whether the induction of cross-reactive Abs confers
protection, K2-immunized mice were challenged with P10H,
P10L and parental PR8 virus and infectious virus in the lungs
determined 5 days later. None of the mice challenged with PR8 or
P10H virus had detectable virus in the lungs at that time
(Figure 4D). After challenge with P10L, K2-immunized mice
showed a 10-fold reduction in P10L virus titers as compared to
Figure 2. Route of immunization with M2e-MAPs determines systemic and respiratory tract responses. BALB/c mice were immunized
with K2 and adjuvants or adjuvants alone either intranasally (i.n.) or into the tailbase (s.c.) as described above. (A) M2e-specific Abs in the bronchio-
alveolar lavage (BAL) fluid after third vaccination were determined by ELISA on M2e-peptide (n=3 mice/group). (B) Sera were collected 3–4 weeks
after the indicated number of immunizations and measured by ELISA for binding to M2e-peptide and HeLa-M2 cells. (C) Mice were euthanized after
third vaccination and cells from lungs and bone marrow (BM) seeded onto ELISPOT plates coated with M2e-peptide. Plates were developed with anti-
mouse IgG or IgA. Results from 4–6 mice from 2 independent experiments are expressed as mean counts (6 SEM). (D) Groups of mice were
challenged with influenza virus A/X31 (1000 TCID50/5 mL) and infectious virus in the lungs determined 5 days after challenge.
doi:10.1371/journal.pone.0028445.g002
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A/FM and B/Lee. (B) Serum Abs of BALB/c mice (n=5 mice) immunized i.n. or s.c. with K2 peptide and adjuvants were tested in an ELISA for binding
to MDCK cells infected with influenza virus A/PR8 (square), A/FM (diamond) and B/Lee (circle). (C) M2e amino acid sequence from the pandemic
influenza strain A/Texas/2009. (D) Sera with anti-M2e Abs induced by i.n. or s.c. immunization with K2 peptide and adjuvants or adjuvants alone were
tested for binding to a synthetic peptide corresponding to the A/Texas/2009 M2e sequence as depicted in (C).
doi:10.1371/journal.pone.0028445.g003
Figure 4. Immunization with M2e-MAP K2 protects against challenge with M2e-variant viruses. (A) Amino acid sequence comparison of
M2e from influenza A/PR8 (P10) or M2e-escape mutant viruses (P10H and P10L) as described in Ref. 9. (B) Sera from BALB/c mice immunized i.n. three
times with K2 peptide and adjuvants were assayed in an ELISA on peptides with M2e sequences as shown in (A) or control peptide cysBB: cysteine
back-bone. (C) Pooled sera (1:250 dilution) from BALB/c mice (n=5 mice) immunized as in (B) were assayed in an ELISA for binding to MDCK cells
infected with influenza virus A/PR/8, the M2e-escape mutants P10H and P10L, A/FM and B/Lee. The monoclonal anti-M2e Ab 14C2 (1 mg/mL) is
shown as control. (D) BALB/c mice (n=5 mice/group) immunized i.n. with K2 peptide and adjuvants were challenged with 1000 TCID50/50 mL
influenza virus A/PR/8, P10H and P10L three weeks after the third vaccine administration. Infectious virus in the lungs was determined 5 days after
challenge.
doi:10.1371/journal.pone.0028445.g004
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with K2 and adjuvants generates a pool of cross-reactive Abs able
to protect against viruses with variant M2e-sequences.
Responses in different inbred and outbred mouse strains
K2 and K3 M2e-MAP constructs contain promiscuous T helper
epitopes and were synthesized with the goal to generate a vaccine
able to be used in a genetically diverse population. To test whether
the K2 and K3 peptide vaccines show efficacy in mouse strains
other than BALB/c mice (H-2
d), we extended our studies to
C57BL/6 (H-2
b) and C3H (H-2
k) mice, as well as the outbred
mouse strains CD1/ICR and Swiss Webster (SW). As summarized
in Table 2, i.n immunization with K2 in combination with the
adjuvants CpG 1826 and CT was able to elicit a significant anti-
M2e Ab response in BALB/c, but not in C57BL/6, C3H, CD1/
ICR and SW mice as measured by ELISA on both M2e-peptide
and HeLa-M2 cells. Likewise, immunization of outbred CD1/
ICR mice with K3 and adjuvants also failed to induce measurable
anti-M2e Abs (data not shown). Moreover, when K2-immunized
mice were challenged with X31 virus to test whether mice were
protected from viral infection, only BALB/c mice had significantly
reduced viral titers in their lungs and noses at day 5 after challenge
(Table 3). Thus, the absence of protection observed in mouse
strains other than BALB/c mice correlates with the failure to elicit
anti-M2e-Abs in these mice following M2e-MAP immunization.
Natural infections generate low Ab responses to M2e, however a
previously reported scheme of multiple infections that has been
shown to elicit small but significant levels of anti-M2e Abs in
BALB/c mice [14,15]. Adopting this strategy, BALB/c, CD1 and
SW mice were infected in 3–4 weeks intervals first with PR8, then
with PR8-Seq14, which evades HA-based neutralization and
thirdly with X31 virus. Both outbred strains elicited a strong anti-
PR8 serum IgG response similar to BALB/c mice (Figure 5A). All
mouse strains generated detectable anti-M2e Abs in their serum
after the third infection as compared to uninfected mice
(Figure 5B), indicating that the B cell repertoire in these strains
was capable of generating anti-M2e Abs.
To determine if the failure to induce anti-M2e Abs in response
to M2e-MAPs was due to a lack of a T cell response in mouse
strains other than BALB/c mice, an in vitro proliferation assay was
performed. BALB/c, C57BL/6 and C3H mice were s.c.
immunized with K2 and adjuvants and cells from the draining
lymph nodes tested for their capacity to incorporate
[3]H-
thymidine. Consistent with previous findings [15], BALB/c mice
showed a proliferative response in vitro during restimulation with
M2e-peptide in a dose-dependent manner, however cells from
immunized C57BL/6 and C3H mice failed to proliferate
(Figure 5C).
To further investigate the genetic restrictions of the B cell
response to M2e we next immunized C57BL/66BALB/c (F1)
mice. As shown in Figure 5D, i.n. immunization with K2 and
adjuvants elicited high anti-M2e-Ab titers against both M2e-
peptide and HeLa-M2 cells. Allotype-specific reagents, Igha for
BALB/c and Ighb for C57BL/6, revealed that B cells from both
strains were capable of producing anti-M2e Abs (Figure 5E). To
examine whether the levels of anti-M2e Abs induced in vaccinated
C57BL/66BALB/c (F1) mice were sufficient to provide protec-
tion, mice were challenged with X31 virus and viral titers
determined. As compared to control-immunized mice, vaccination
with K2 peptide resulted in significantly reduced viral titers in the
lungs (Figure 5F). Together, these results suggest that B cells from
C57BL6 mice are able to recognize and respond to the M2e-MAP
vaccination.
Discussion
Anti-M2e Abs are poorly induced in humans by infection or
current vaccines [12,47], however several studies have shown the
efficacy of anti-M2e Abs in protective anti-viral immunity. To
improve anti-viral resistance, we evaluated a vaccine strategy with
modified M2e-based multiple antigenic peptides. We investigated
the nature and specificity of the M2e-specific B cell response using
M2e-MAPs termed K2 and K3. Importantly, we assessed the
ability of these M2e-MAPs to confer protection against viral
challenge with homologous and M2-variant viruses and extended
Table 2. Anti-M2e Ab induction in various mouse strains
following vaccination.
M2e-assay Mouse strains Groups
Adjuvants K2+Adjuvants
M2e-peptide BALB/c (I-A
d, I-E
d) 2.262.3 783.9±243.8
C3H (I-A
k, I-E
k) ,1 1.0±0.3
C57BL/6 (I-A
b, I-E
o) ,1 ,1
CD1/ICR 1 2.5
Swiss Webster 1 2.5
HeLa-M2 BALB/c (I-A
d, I-E
d) 261.9 407.9±206.6
C3H (I-A
k, I-E
k) ,1 ,1
C57BL/6 (I-A
b, I-E
o) ,1 ,1
CD1/ICR ,1 7.6
Swiss Webster ,1 ,1
BALB/c (n=21), C3H (n=5), C57BL/6 (n=3), CD1/ICR (n=7) and Swiss Webster
(n=5) mice were immunized i.n. with adjuvants CpG 1826 and CT alone or K2
and adjuvants. After the 3
rd immunization sera were tested for M2e-specific Abs
(in mg/mL) by ELISA on M2e-peptide and HeLa-M2 cells as indicated. Results are
displayed as mean 6 SD or results are shown from pooled samples.
doi:10.1371/journal.pone.0028445.t002
Table 3. Viral titers in lungs and nose of X31-challenged mice
following vaccination.
Virus titers Mouse strains Groups
Adjuvants K2+Adjuvants
Lungs BALB/c (I-A
d, I-E
d) 5.861.0 2.0±0.7
C3H (I-A
k, I-E
k) 4.160.8 4.1±1.6
C57BL/6 (I-A
b, I-E
o) 5.761.0 4.8±0.6
CD1/ICR 5.160.3 4.3±1.6
Swiss Webster 5.060.1 4.9±0.7
Nose BALB/c (I-A
d, I-E
d) 4.860.3 3.3±0.7
C3H (I-A
k, I-E
k) 4.860.2 4.6±0.2
C57BL/6 (I-A
b, I-E
o) 4.860.1 5.1±0.6
CD1/ICR 5.160.2 5.1±0.3
Swiss Webster 5.260.6 5.2±0.4
BALB/c (n=21), C3H (n=5), C57BL/6 (n=3), CD1/ICR (n=7) and Swiss Webster
(n=5) mice were immunized three times i.n. with adjuvants CpG 1826 and CT
alone or K2 and adjuvants and tested for their protection against viral challenge
with X31 virus (1000 TCID50 in 5 mL). Virus titers in lungs and noses were
determined 5 days after challenge. Results are displayed as mean 6 SD.
doi:10.1371/journal.pone.0028445.t003
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mouse strains.
Previously, immunization of BALB/c mice with a first-generation
M2e-MAP, termed G40d, in combination with the adjuvants CpG
and CT was shown to induce M2e-specific serum Abs and local
immunity in the respiratory tract (RT) [14,15]. We extended these
studies usingnew M2e-MAPs that weregeneratedusing a simplified
peptide synthesis that is more compatible with large-scale
production and also incorporated promiscuous T helper epitopes
that might be recognized by multiple haplotypes. Others have
shown that the N-terminal 15 amino acid M2e peptide by itself is
poorly immunogenic and failed to elicit a robust anti-M2e-Ab
response in BALB/c mice in a prime-boost immunization [21]. We
show here that immunization of BALB/c mice with K2 and K3 in
combination with the adjuvants, CpG and CT, induced high M2e-
specific serum Ab titers (Figure 1B). Of note, these Ab titers
exceeded the detected levels in previous studies with G40d [14,15],
although the amount of anti-M2e Abs necessary for protection has
not been determined. Anti-M2e Abs are not virus-neutralizing, but
they can restrict viral replication and transmission, and passive
transfer of anti-M2emonoclonal Absin mice results in reduced viral
titers, accelerated viral clearance and thus protection
[5,7,8,9,10,11]. Likewise, mice vaccinated with either K2 or K3
had significantly reduced viral titers when challenged with X31
virus and this protection extended to challenge with the more
pathogenic PR8 virus (Figure 1C and 1D).
It has been hypothesized that the induction of local immunity at
the site of virus entry, such as the mucosal surfaces of the nasal
Figure 5. Genetic impact on anti-M2e immunity. (A and B) BALB/c, CD1/ICR and Swiss Webster (SW) mice (n=5–6 mice) received three
consecutive infections, first with influenza virus A viruses PR8, secondly with PR8-SEQ14 and thirdly with X31. PR8-specific IgG (A) and M2e-specific
IgG (B) in sera were determined after first and third infection, respectively. The results of sera from naive mice (n=1/mouse strain) were pooled. (C)
BALB/c, C57BL/6, and C3H mice were immunized s.c. with K2 peptide and adjuvants or adjuvants alone. The draining lymph node was harvested on
day 8 and proliferation was assessed by incorporation of
[3]H-thymidine during the fourth day of an in vitro culture in presence of K2 peptide. One out
of two independent experiments shown. (D–F) BALB/cxC57BL/6 (F1) mice (n=5 mice) were immunized i.n. with K2 and adjuvants or adjuvants alone.
(D) M2e-specific Ab titers measured in an ELISA against M2e-peptide or HeLa-M2 cells in serum of BALB/cxC57BL/6 (F1) mice after third
immunization. (E) M2e-specific serum Abs at a 1:150 serum dilution were determined with allotype-specific reagents (IgG2a[a] and IgG1[a] for BALB/c
and IgG2c and IgG1[b] for C57BL/6 origin). (F) After the third immunization, BALB/cxC57BL/6 (F1) mice were challenged with X31 (1000 TCID50/5 mL)
and infectious virus in the lungs was determined 5 days post challenge.
doi:10.1371/journal.pone.0028445.g005
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protection to influenza virus infection (reviewed in [48,49]). Work
by several investigators has suggested that IgA in (upper) RT
secretions in addition to IgG, the predominant isotype in the
serum, plays a major role in antiviral immunity [50,51,52,53]. We
have compared the i.n. to s.c. route of K2 administration for their
ability to induce M2e-specific IgA and IgG Abs and to promote
protection. We show that the presence of M2e-specific IgA in BAL
was dependent on i.n. administration of M2e-MAPs and
correlated with IgA-producing cells in the RT (Figure 2A and
2C). On the other hand, s.c. immunization induced significantly
higher Ab levels in the serum and was as efficient as i.n.
immunization in inducing M2e-specific IgG in the BAL
(Figure 2A and 2B). Our data are consistent with findings by
other groups that i.n. vaccinations with live-attenuated influenza
vaccine (LAIV), viral-like particles or inactivated viruses generate
strong local Ab responses in the RT, in particular the induction of
IgA, whereas parenteral/s.c. immunization elicits strong Ab
responses in the serum but little IgA in the RT [28,46,54].
However, in contrast to these studies, we demonstrate that the
protection of i.n. and s.c. immunized mice to challenge with X31
virus was similar (Figure 2D), suggesting that the absence of M2e-
specific IgA in BAL after s.c. immunization can be compensated
for high titers of anti-M2e IgG in BAL and serum. Our findings
support recent observations in IgA
2/2 mice that suggest that IgG
is sufficient for M2-induced anti-viral immunity [26,37].
Ideally, an influenza vaccine should induce broadly cross-
reactive immunity and protection against variant viruses. We show
that vaccination with K2 induced serum Abs that not only
recognized the M2 sequence of PR8 used in the vaccine, but also
bound efficiently to cells infected with influenza virus A/FM
(Figure 3B), recognized M2e peptide from the pandemic H1N1
(Figure 3D) and provided protection to challenge with the
mutant viruses P10L and P10H (Figure 4B-D). These results
suggest that immunization with the M2e-MAPs induces Abs that
might also be cross-reactive against certain types of avian viruses
that have similar exchanges at amino acid position 10, which have
been observed among recent H5, H7 and H9 isolates [9,24,25].
Our data corroborate the findings of other studies with M2e-based
MAPs and contribute to the growing evidence that M2e-based
vaccines are able to provide cross-reactive protection
[19,25,26,38,55]. Furthermore, we demonstrate that induction of
cross-reactive Abs can depend on the route of immunization in
that s.c. as compared to i.n. administration induced higher levels
M2e-specific Abs (Figure 2B) and thereby increasing the overall
avidity of potentially cross-reactive anti-M2e Abs (Figure 3D).
Finally, we evaluated the response to K2 and K3 in other inbred
and outbred mouse strains. In contrast to our findings in BALB/c
mice, C57BL/6, C3H and the outbred mouse strains CD1/ICR
and Swiss Webster exhibited poor anti-M2e Ab levels after
vaccinations with K2 and K3 and were not protected from viral
challenge (Table 2, data not shown and Table 3). Likewise,
others have reported a genetic restriction to M2e-based vaccines
[37]. Zhang et al. has demonstrated that the anti-M2e response in
BALB/c mice was comprised of a set of highly restricted
immunoglobulin genes usage [56]. This finding could explain in
part the low Ab titers after natural infection as well as the
unresponsiveness we observed in other mouse strains. However,
we demonstrate that multiple infections in outbred mice induced a
small but detectable serum Ab response to M2e (Figure 5B).
Moreover, M2e-specific Abs from both BALB/c and C57BL/6
allotypes were detected in vaccinated BALBxB6 F1 mice
(Figure 5E), indicating that the lack of an Ab response to M2e-
MAPs in C57Bl/6 mice was not due to an inherent failure of B
cells from this background to recognize M2e.
A key feature of the modified M2e-MAPs used in this study is
that they contain potentially universal T cell determinants. The T
cell epitopes included in K2 and K3 vaccine constructs have
previously been tested for promiscuity and were shown to bind
many HLA-DR molecules [44,45,57]. While efficacy in inducing
T cell responses is variable and shows some genetic dependence,
other studies demonstrated that the T cell epitope CS327–345
induces responses in C57BL/6 mice and non-human primates as a
linear or branched peptide together with water-in-oil based
adjuvants or CpG [58,59]. Likewise, a MAP-combination of
CS381–396 with the B cell epitope (NANP)3 induces responses in
multiple inbred mouse strains [57]. Additionally, polypeptide
constructs with multiple T cell epitopes, including HA307–319,
HbsAg19–33, and CS381–396 conjugated to Haemophilus influenzae
polysaccharide elicit Ab titers in CD1 outbred mice [43].
However, we were unable to detect T cell responses in C57BL/
6 and C3H mice after s.c. immunization with K2 and adjuvants
(Figure 5C). Thus, the lack of a T cell response to the
immunizing M2e-MAP peptide could explain the lack of
measurable M2e-specific Abs.
A fully synthetic peptide vaccine based on a highly conserved
viral antigen has the advantage that its preparation does not
include undesirable components from the purification processes of
live whole organisms and that it does not require yearly
adjustments. However, the main question that still needs to be
addressed for this vaccine approach is how to improve its
immunogenicity. Although we have not formerly shown that the
adjuvants used in this study, CpG and CT, have comparable
effects in different mouse strains, studies by others suggest that
their adjuvant activity is independent of genetic backgrounds
[60,61]. Embedding additional adjuvant sequences into MAPs as
well as incorporating other conserved immunogenic viral target
proteins, such as NP and HA, for a combination therapy have
been shown to exceed protective efficacy compared to single
antigens and may enhance their therapeutic potential [29]. Rapid
manufacturing of an influenza vaccine based on M2e-containing
MAP constructs provided with optimal T cell help may be an
attractive alternative for the production of current influenza
vaccines.
Materials and Methods
Ethics Statement
All animal studies were performed under the approved protocol
#112046 issued by the Wistar Institutional Animal Care and User
Committee.
Mice
Female mice, including the inbred mouse strains BALB/c,
C57BL/6, C3H and BALB/cxC57BL/6 (F1) mice and outbred
mouse strains, CD1/ICR and Swiss Webster, 8–10 weeks old,
were purchased from the National Cancer Institute and Charles
River laboratories. All mice were housed at the Wistar Institute
under specific pathogen free/viral antibody free conditions.
Peptides
Multi-antigenic peptide constructs, designated K2 and K3 were
synthesized containing 4 side chains of M2e (SLLTEVETPIR-
NEWG) and 2 pairs of T helper determinants from the circum-
sporozoite protein from Plasmodium falciparum (CS381–396 KKIAK-
MEKASSVFNVV and CS327–345 YLNKIQNSLSTEWSPCSVT),
or the hepatitis B virus antigen (HbsAg19–33 FFLLTRILTIPQSLD
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TLKLAT) and are depicted in Table 1.
The linear M2e peptide from the pandemic influenza virus A/
Texas/05/2009 (H1N1) was synthesized based on the sequence
according to GenBank Accession number FJ966968.1.
Peptides with M2e-sequence from escape mutants of influenza
virus PR8, termed P10H and P10L were described previously [9].
Immunization
The immunization protocol was adopted from Mozdzanowska
et al. [14,15]. In brief, 50 mL sterile PBS containing 5 mg of M2e-
MAPs K2 or K3 (see Table 1) together with the adjuvants CpG
ODN 1826 (3 mg, Sigma) and cholera toxin (CT, 0.5 mg, Sigma)
or adjuvants alone were administered intranasally (i.n.) or
subcutaneously (s.c., into the tail base) into anesthetized mice
(ketamine/xylazine, 70/7 mg/kg). Vaccinations were repeated
twice in 3–4 weeks intervals.
Sample collections and tissue preparation
Prior to each vaccination, blood samples were collected from
each immunization group by mandibular bleeding or obtained
from the tail vein. Tissues were collected and cells prepared as
described [62]. In brief, mice were euthanized by CO2 asphyxa-
tion and blood was collected through cardiac puncture. BAL was
harvested by flushing the airway compartment with 0.8 mL PBS
with 1% FBS (PBS/FBS) 3 times. Perfused lungs were digested in
HBSS with 400 U/mL Collagenase D (Roche) for 30 min at
37uC. Cells from bone marrow were prepared from 2 hind legs of
mice. Tissues were passed through metal wire mesh and after red
blood cell lysis, cells resuspended in Iscove’s complete medium
containing 10% FBS for ELISPOT assays.
For viral titers (see below), noses and lungs dissected after
exsanguinating mice and tissues were stored at 280uC until
processed for virus titration.
Viruses and infection
The following viruses were used in this study: A/PR/8/34
(PR8, H1N1), A/HKx31 (X31, H3N2), A/FM1/49 (FM, H1N1)
and influenza B/Lee/40 (B/Lee). The virus escape mutants P10H
and P10L are viral isolates that emerged from PR8-infected SCID
mice, which had been chronically treated with M2e-specific Ab
14C2 and have been described elsewhere [9]. For challenge
experiments, a viral dose of 1000 TCID50 was administered i.n.
into anesthetized mice (ketamine/xylazine, 70/7 mg/kg) in 5 mL
or 50 mL sterile PBS as indicated.
Virus titer
To determine protection of vaccinated mice, titers of infectious
virus were measured in noses and lungs 4 and 5 days after viral
challenge as described previously [63,64]. Tissues were homoge-
nized in sterilized mortars and transferred to a tube, and
centrifuged for 5 min at 4006g (1300 rpm). The supernatant
was tested for concentration of infectious virus in the Madin-
Darby canine kidney cells (MDCK) assay [64]. Lung titers are
expressed as dilution of lung extract at which 50% of the MDCK
cultures revealed virus growth (TCID50/mL).
In vitro infection of MDCK cells
Influenza strains PR8, FM, B/Lee, P10H and P10L were used
for in vitro infection of MDCK cultures as described [9]. In brief,
MDCK cells (ATCC) were grown to form confluent monolayers in
flat-bottom 96-well Falcon Microtest plates (Becton Dickinson).
Monolayers were infected by incubation (90 min at 37uC) with
50 mL of virus (,10
6 TCID50). Typically, eight replicate cultures
were infected with a given dilution of a virus isolate. After 90 min,
100 mL of Iscove’s media, 5% FCS was added to each well, and
incubation was continued as described above for another 7 to 8 h.
Monolayers were then washed with PBS, fixed by incubation with
5% buffered formalin (Fisher Scientific) for 5 min at room
temperature, washed again with PBS, and blocked and stored
with PBS, 1% BSA at 4uC. The infected MDCK cell monolayers
were then tested for reaction with immune sera from vaccinated
mice or M2e-specific monoclonal Ab (1 to 2 mg/mL) as standard
as described in the ELISA protocol below.
ELISA and ELISPOT assay
Measurement of M2e-specific Antibodies by ELISA was
performed as described [12,14,15]. In brief, two approaches were
taken to measure M2e-specific Ab by ELISA; immunosorbents
cys-M2e peptide and control peptide (cys-backbone) or HeLa cells
stably transfected with M2 (HeLa-M2) or empty control plasmid
(HeLa-C10) were used to distinguish between specific and non-
specific binding [12,14,15]. HeLa-M2 and HeLa-C10 cells were
obtained from Dr. Gerhard (The Wistar Institute). Each assay was
standardized and quantified by titration of purified M2e-specific
mAb 14C2-S1-4 (G2a) on the same immunosorbents and Ab titers
in test samples were defined as anti-M2e Ab equivalent. PR8-
specific Abs were standardized based on purified anti-HA Ab
standard H36-4-5.2 (G2a). Abs in serum or BAL samples were
detected with biotinylated mAb 187 and subsequent avidine-
coupled to alkaline phosphatase (AP) or anti-mouse IgG- or IgA-
AP and developed with pNPP as described (Sigma). The difference
in optical density (OD) between specific and non-specific
immunosorbent was used for quantification of Ab concentration.
ELISA data were collected with an E-max ELISA reader and
analyzed with Softmax Pro software (Molecular Devices).
To detect M2e-specific ASCs, the same immunosorbents were
used to coat ELISPOT plates (Millipore). Cell suspensions from
various organs were titrated and incubated for 6–7 h at 37uCi na
humidified incubator with 5% CO2. Immunosorbent-bound Abs
were detected with anti-mouse IgG- or IgA-AP and developed
with NBT/BCIP substrate (Sigma). Automated spot counts were
performed with an ImmunoSpot Reader (CTL) and Immunospot
satellite software (CTL).
Proliferation assay
Mice were immunized s.c. with 50 mL sterile PBS containing
10 mg of K2 peptide together with adjuvants or adjuvants alone
into both flank sides. Eight days following immunization, mice
were euthanized and draining inguinal lymph nodes as well as
spleens harvested. For preparation of antigen presenting cells,
spleens were processed into single cell suspensions as described,
resuspended at 5610
6/mL in Iscove’s media, 10% FBS and
irradiated with 2000 rad using a cesium source. 0.5610
6
responder cells from the inguinal lymph node were cultured in a
96 well plate with an equal number of irradiated splenocytes in the
presence of indicated concentrations of K2 peptide. Three days
later,
[a]H-thymidine was added (1 mCi/well) and plates harvested
after 24 h as described [15].
Statistics
Data are presented as mean 6 standard error of the mean
(SEM). Statistical significance between two groups was calculated
using the unpaired Student’s t-test. For three and more groups,
one-way ANOVA with multiple comparison post-test was used.
Statistical significance with data below detection limit was
calculated using a two-part t-test or Fisher’s exact test. Statistical
M2e-Mediated Antiviral Protection
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P-values are depicted as follows: ns (not significant), p.0.05;
*, p,0.05; **, p,0.01 and ***, p,0.001.
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